Nemolizumab Treatment for Severe Atopic Dermatitis Led to the Simultaneous Improvement of Coexisting Refractory Alopecia Areata: A Case Report
November 2025
in “
The Journal of Dermatology
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → Studysummary In this case report, a Japanese woman with both atopic dermatitis and alopecia areata showed improvement in both conditions following treatment with nemolizumab.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This case report describes a 56-year-old Japanese woman with severe atopic dermatitis (AD) and coexisting refractory alopecia areata (AA) who was treated with nemolizumab, an anti-IL-31 receptor A monoclonal antibody. Despite previous unsuccessful treatments for AA, nemolizumab, administered for AD, led to a 90% improvement in the Eczema Area and Severity Index (EASI) score and a simultaneous decrease in the Severity of Alopecia Tool (SALT) score after 3 months. The report suggests that nemolizumab may suppress the JAK–STAT pathway, potentially improving AA, although its use is only approved for severe AD. This single case highlights the potential benefit of controlling AD activity for managing coexisting AA, though the improvement in AA could be coincidental.
